Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Autor:
Tobias Herold, Luise Hartmann, Wolfgang Hiddemann, Philipp A. Greif, Daniela Schumacher, Bianka Ksienzyk, Claudia D. Baldus, Bernhard Wörmann, Evelyn Zellmeier, Stephan Wolf, Sebastian Vosberg, Friederike Pastore, Helmut Blum, Stephanie Schneider, Sophie M. Stief, Stefanos A. Bamopoulos, Wolfgang E. Berdel, Ines Hellmann, Stefan Krebs, Alexander Graf, Karsten Spiekermann, Klaus H. Metzeler, Stefan K. Bohlander, Vindi Jurinovic, Nikola P. Konstandin, Raphael Mattes, Dennis Görlich, Martin Neumann, Kathrin Bräundl, Paul Kerbs
Publikováno v:
Clinical Cancer Research. 24:1716-1726
Purpose: To study mechanisms of therapy resistance and disease progression, we analyzed the evolution of cytogenetically normal acute myeloid leukemia (CN-AML) based on somatic alterations. Experimental Design: We performed exome sequencing of matche
Autor:
Jean-Claude Souberbielle, Thierry Capiod, Arnaud Mejean, Stéphane Oudard, Nicolas Barry Delongchamps, Edouard Reyes-Gomez, Florence Boutillon, Natascha Pigat, Mélanie Viltard, Virginie Verkarre, Eve M. Lepicard, Vincent Goffin, Sophie Bernichtein, Philippe Camparo, Gérard Friedlander
Publikováno v:
Cancer Research. 77:355-365
Active surveillance has emerged as an alternative to immediate treatment for men with low-risk prostate cancer. Accordingly, identification of environmental factors that facilitate progression to more aggressive stages is critical for disease prevent
Autor:
Stephen N. Thibodeau, Michelle R. Mahoney, Richard M. Goldberg, Harry H. Yoon, Daniel J. Sargent, Thomas C. Smyrk, Steven R. Alberts, Frank A. Sinicrope, Garth D. Nelson
Publikováno v:
Clinical Cancer Research. 21:5294-5304
Purpose: To determine the frequency and prognostic association of molecular markers by anatomic tumor site in patients with stage III colon carcinomas. Experimental Design: In a randomized trial of adjuvant FOLFOX ± cetuximab, BRAFV600E and KRAS (ex
Autor:
Alexandra M. Ward, Marek Kimmel, Heath D. Skinner, Thomas J. Ow, Ameeta A. Patel, Thomas O. McDonald, David M. Neskey, Paolo Bossi, Teng-Kuei Hsu, Jeffrey N. Myers, Mei Zhao, Federica Perrone, Abdullah A. Osman, Panagiotis Katsonis, Adel K. El-Naggar, Marcus V. Ortega Alves, Curtis R. Pickering, Erich M. Sturgis, Stephanie C. Hicks, Merrill S. Kies, Lisa Licitra, Olivier Lichtarge, Mitchell J. Frederick
Publikováno v:
Cancer Research. 75:1205-1215
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the cu
Autor:
Chen Jiang, Alan P. Venook, Alexander B. Sibley, Ivo D. Shterev, Kouros Owzar, Herbert Hurwitz, Stephanie M. Cushman, Andrew B. Nixon, Donna Niedzwiecki, Ace J. Hatch
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 5
Purpose: Formalin-fixed, paraffin-embedded tumor samples from CALGB 80203 were analyzed for expression of EGFR axis–related genes to identify prognostic or predictive biomarkers for cetuximab treatment. Patients and Methods: Patients (238 total) wi
Autor:
Rebeca Manso, Cristina Caramés, Jesús García-Foncillas, Sandra Zazo, Juan Madoz-Gúrpide, Federico Rojo, Ion Cristóbal, Raúl Rincón
Publikováno v:
Clinical Cancer Research. 21:347-356
Purpose: SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic co
Autor:
Chinthalapally V. Rao, Naveena B. Janakiram, Rebekah L. Ritchie, Vernon E. Steele, Altaf Mohammed, Stan Lightfoot, Laura Biddick, Venkateshwar Madka, Jagan M.R. Patlolla, Misty Brewer, Michael Sadeghi
Publikováno v:
Cancer Prevention Research. 7:1198-1209
Ornithine decarboxylase (ODC) is the key rate-limiting enzyme in the polyamine synthesis pathway and it is overexpressed in a variety of cancers. We found that polyamine synthesis and modulation of ODC signaling occurs at early stages of pancreatic p